Why does Medicare Part D exclude weight loss drugs?
The core of the coverage issue is a statutory exclusion in the Medicare Modernization Act of 2003. Section 1860D-2(e)(2) of the Social Security Act explicitly excludes “agents when used for anorexia, weight loss, or weight gain” from Part D coverage. This exclusion was written well before GLP-1 receptor agonists became the dominant class of weight management therapy — the drafters were primarily thinking about stimulants, appetite suppressants, and similar agents with poor safety profiles.
The result is a structural coverage gap: a GLP-1 medication like semaglutide, prescribed primarily for weight management, typically falls outside Part D coverage, regardless of its clinical evidence base. The same drug, prescribed for Type 2 diabetes, may be fully covered under a beneficiary’s formulary.
Does the diabetes vs. weight-management indication change what Medicare will cover?
Yes — the indication driving the prescription, not just the drug itself, determines coverage eligibility under Part D. Here is how coverage differs across the main GLP-1 formulations:
| Drug (brand) | Approved indication | Medicare Part D coverage |
|---|---|---|
| Ozempic (semaglutide 0.5–2 mg) | Type 2 diabetes | May be covered under Part D with diabetes diagnosis |
| Wegovy (semaglutide 2.4 mg) | Chronic weight management | Generally not covered; some MA plans add as supplemental benefit |
| Mounjaro (tirzepatide) | Type 2 diabetes | May be covered under Part D with diabetes diagnosis |
| Zepbound (tirzepatide) | Chronic weight management | Generally not covered under standard Part D |
This coverage dichotomy creates a frustrating situation for many Medicare beneficiaries who have genuine clinical need for GLP-1 therapy for weight management but do not have a concurrent diabetes diagnosis.
The rule blocking Medicare from covering GLP-1 weight-loss drugs was written in 2003 — years before these medications existed — and only an Act of Congress can change it.
How does the Inflation Reduction Act affect GLP-1 coverage prospects?
The Inflation Reduction Act of 2022 directed CMS to study expanding Part D coverage to include anti-obesity medications. CMS released a report acknowledging the clinical evidence supporting GLP-1 therapies and the equity concerns around the coverage exclusion — but the report did not change the statutory exclusion. Changing that exclusion requires an Act of Congress.
Multiple legislative proposals have been introduced to remove or modify the Part D anti-obesity medication exclusion. As of mid-2026, none have passed. The proposals have bipartisan support in concept but have faced opposition related to the projected cost to the Medicare program — GLP-1 medications at scale represent an enormous potential liability.
The cardiovascular data from the SELECT trial (which demonstrated a significant reduction in major adverse cardiovascular events with semaglutide in patients with established cardiovascular disease) has shifted the political conversation. Some Part D plans have moved to cover Wegovy for beneficiaries with established cardiovascular disease, even absent a broader statutory change.
How does Medicare Advantage cover GLP-1 medications?
Medicare Advantage (Part C) plans have more flexibility than traditional Medicare to offer supplemental benefits not covered under Part A or Part B. A small but growing number of Medicare Advantage plans have added GLP-1 weight management medications as supplemental benefits — meaning beneficiaries enrolled in those specific plans may have coverage that traditional Medicare does not offer.
If you are enrolled in Medicare Advantage, here is how to check:
- Request the current year’s Evidence of Coverage (EOC) from your plan and search for “anti-obesity” or “GLP-1” in the supplemental benefits section.
- Review your plan’s drug formulary, available at Medicare.gov. Look for semaglutide (Wegovy) or tirzepatide (Zepbound) specifically — not just Ozempic or Mounjaro, which carry diabetes indications.
- Call your plan’s member services line and ask directly whether GLP-1 medications for obesity are covered with your diagnosis.
Coverage landscapes shift during annual enrollment periods, so a plan that did not cover GLP-1 therapy last year may have added it — or vice versa.
What are your out-of-pocket options when Medicare coverage is unavailable?
For Medicare beneficiaries who cannot obtain GLP-1 coverage under their current plan, the self-pay landscape in 2026 offers several paths:
Branded GLP-1 manufacturer programs
Novo Nordisk and Eli Lilly offer savings programs, but most manufacturer assistance programs explicitly exclude Medicare beneficiaries (due to federal anti-kickback concerns around patients with federal health coverage). Verify eligibility directly with the manufacturer before relying on these programs.
Compounded GLP-1 peptides via telehealth
Compounded semaglutide and tirzepatide — prescribed by a licensed clinician and compounded by a licensed 503A pharmacy — are not covered by Medicare. However, they are available on a self-pay basis at considerably lower cost than branded alternatives. Because these are compounded in the USA by licensed 503A pharmacies with no hidden overseas supply chain, they represent a quality-controlled path for patients who cannot access covered branded therapy.
Important: compounded peptides are not FDA-approved drugs. They are prepared under the 503A compounding framework, which permits individual patient prescriptions from licensed compounding pharmacies. A licensed clinician evaluates your history and prescribes if appropriate.
Medical weight management programs
Some Medicare Advantage plans cover “intensive behavioral therapy for obesity” as a Part B benefit. While this doesn’t cover the medication itself, it may cover counseling that supports a broader weight management effort. Check with your specific plan.
What to tell your clinician
If you are a Medicare beneficiary seeking GLP-1 therapy, having an informed conversation with your clinician improves your options. Key points to discuss:
- Whether you have any qualifying comorbidities (Type 2 diabetes, established cardiovascular disease) that might support a covered indication
- Whether your Medicare Advantage plan has any supplemental GLP-1 benefit (bring your formulary)
- Self-pay compounded options if covered therapy is unavailable
- The clinical evidence supporting GLP-1 therapy for your specific situation
The coverage landscape for GLP-1 and Medicare is one of the most rapidly evolving areas in healthcare policy. Checking with your plan at each annual enrollment period is the only way to stay current.
Frequently asked questions
Does Medicare cover GLP-1 medications for weight loss?
As of 2026, Medicare Part D does not broadly cover GLP-1 medications prescribed solely for weight management. The Inflation Reduction Act directed CMS to study coverage, but a statutory exclusion on weight loss drugs in Part D has historically blocked coverage. GLP-1 medications prescribed for Type 2 diabetes management (e.g., Ozempic) may be covered under Part D, but the same drug prescribed for weight loss alone typically is not covered.
Is semaglutide covered by Medicare?
Semaglutide branded as Ozempic may be covered under Part D when prescribed for Type 2 diabetes with appropriate diagnosis codes. Wegovy (semaglutide for weight management) has generally not been covered under Part D for beneficiaries without a qualifying cardiovascular condition or diabetes diagnosis. Coverage details vary by specific Part D plan and formulary.
What about compounded GLP-1 peptides — does Medicare cover those?
Medicare does not cover compounded medications, including compounded semaglutide or tirzepatide, under Part D. Compounded peptides must be obtained on a self-pay basis. They are compounded in the USA by licensed 503A pharmacies and prescribed by a licensed clinician, but they fall outside the Part D coverage framework.
When might Medicare coverage for GLP-1 expand?
CMS has faced growing pressure from advocacy groups and Congress to remove the Part D exclusion for anti-obesity medications. Legislative proposals have been introduced in multiple sessions but have not yet passed as of 2026. Beneficiaries with a qualifying cardiovascular indication (as studied in the SELECT trial) have had better coverage outcomes in some plans.
What are out-of-pocket costs for GLP-1 medications without Medicare coverage?
Branded GLP-1 medications like Ozempic or Wegovy can run $900–$1,300/month without insurance coverage. Compounded semaglutide through a licensed 503A pharmacy via a telehealth provider typically costs significantly less on a self-pay basis, making it the most accessible path for Medicare beneficiaries who cannot obtain covered branded GLP-1 therapy.
Does Medicare Advantage cover GLP-1 differently than traditional Medicare?
Some Medicare Advantage (Part C) plans include supplemental benefits that traditional Medicare does not offer, and a small number have added GLP-1 weight management coverage as a supplemental benefit. Coverage varies dramatically by plan, insurer, and geographic market. Review your specific plan's Evidence of Coverage and formulary to determine what applies to you.